Genetically modified autologous T-cell therapy (Neovii Biotech)

N/A

Report date: 2023/02/18 19:47:24

Base Information

Drug NameGenetically modified autologous T-cell therapy (Neovii Biotech)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsHIV Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNeovii Biotech Gmbh

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNeovii Biotech Gmbh

Active IndicationsN/A

Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A